title: A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.
abstract: OBJECTIVE
  To assess the efficacy and safety of infliximab for the treatment of psoriasis in a meta-analysis framework.
  
  
  METHODS
  Data were extracted by searching the EMBASE (1974-2014), PubMed(1966-2014) and the Cochrane library2013.4th databases. Only randomized and placebo-controlled studies were selected in this study.
  
  
  RESULTS
  Statistically significant differences in efficacy were found for the infliximab (3 or 5 mg/kg) group compared with the control group which received placebo in the treatment of psoriasis vulgaris [OR 13.55, 95%CI (11.14,16.48)]or[OR85.45, 95%CI (39.13,186.58)]. There were also significant differences in efficacy between the infliximab (5 mg/kg) group and the placebo control group during treatment of psoriasis arthritis (PsA) [OR8.36, 95%CI (5.63, 12.40)]. A controlled trial used infliximab (5 mg/kg) in the treatment of palmoplantar psoriasis. This study showed that the effective rate of the infliximab group was 33.3% (4/12) when compared to the placebo control group, which was 8.3% (1/12).
  
  
  CONCLUSIONS
  Infliximab is significantly associated with symptom relief, skin lesion improvement, and an increase in the quality of life of psoriasis patients. The most common drug-induced adverse events were pain, hepatic dysfunction, and infusion reaction.
authors.affiliation: a Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital ; Tianjin , China.
authors.forename: Jin
authors.initials: J
authors.lastname: Wang
authors.affiliation: a Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital ; Tianjin , China.
authors.forename: Qingxia
authors.initials: Q
authors.lastname: Zhan
authors.affiliation: a Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital ; Tianjin , China.
authors.forename: Litao
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000328:Adult; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000069285:Infliximab / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
keywords: Infliximab; meta-analysis; psoriasis; systematic review